טוען...
Therapeutic Updates for Relapsed and Refractory Classical Hodgkin Lymphoma
SIMPLE SUMMARY: The approach to relapsed and refractory classical Hodgkin lymphoma is rapidly evolving. Over the past five years, we have seen the arrival of novel immunotherapies with impressive clinical response rates. These agents are actively being investigated earlier in the sequence of therapi...
שמור ב:
| הוצא לאור ב: | Cancers (Basel) |
|---|---|
| Main Authors: | , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
MDPI
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7601361/ https://ncbi.nlm.nih.gov/pubmed/33050054 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12102887 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|